London
· Delayed Price · Currency is GBP · Price in USD Adicet Bio Company Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications.
The company was founded in 2014 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Chen Schor |
Contact Details
Address: 131 Dartmouth Street Boston, Delaware 02116 United States | |
| Phone | 650 503 9095 |
| Website | adicetbio.com |
Stock Details
| Ticker Symbol | 0HX7 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0070021086 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor | Chief Executive Officer |
| Brian Harvey | Chief Financial Officer |